login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Boston Scientific launches Ingenio and Advantio family of pacemakers in Europe


Wednesday, 11 Apr 2012 10:29

Boston Scientific has announced CE mark approval and European market launch of its Ingenio and Advantio pacemakers and  Invive cardiac resynchronisation therapy pacemakers (CRT-P). Marc Burban performed one of the first implants of the Ingenio on the first week of April at the Nouvelles Cliniques Nantaises in Nantes, France. 


“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimise and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”

“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities, that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems - all designed to provide innovative new features for patient health and well-being.”


The Ingenio and Advantio pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence. RightRate employs Boston Scientific’s minute ventilation sensor, the only sensor clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.


The Ingenio and Advantio pacemakers are currently under review by the US Food and Drug Administration (FDA), and are currently not available for sale in the United States.




Add New Comment

Most popular


Benefit of anticoagulation in AF patients with a low risk of stroke questioned
Thursday, 18 Jun 2015
The results from a retrospective study, based on a large dataset (over 140,000 patients), have cast doubt on the benefit of routine oral anticoagulants for patients with atrial fibrillation and low ... Benefit of anticoagulation in AF patients with a low risk of stroke questioned

Wednesday, 13 May 2015
The agreement will bring real-time, patient-specific heart electrical activity data to cardiac electrophysiology labs around the world to speed up the diagnosis of the sources of atrial fibrillation ... Abbott and GE Healthcare announce agreement to improve atrial fibrillation treatment

Reversal agents may help to quell fears of major bleeding with novel oral anticoagulants
Tuesday, 26 May 2015
The availability of reversal agents for NOACs may help to dissipate fears amongst the medical community and patients about life-threatening haemorrhagic complications with NOACs. Cardiac Rhythm News ... Reversal agents may help to quell fears of major bleeding with novel oral anticoagulants

Features


Advanced technologies to improve efficacy and safety of AF ablation
Thursday, 18 Jun 2015
David Keane (Dublin, Ireland) reviews electrical indices, ultrasound, light, infrared, ultraviolet light with fluorescence and microwave technologies to improve efficacy and safety of AF ablation. Advanced technologies to improve efficacy and safety of AF ablation

Targeting the left atrial appendage for AF-related stroke prevention: Why the heart team is necessary
Wednesday, 06 May 2015
Sacha Salzberg cardiovascular surgeon comments on catheter-based and surgical approaches for left atrial appendage occlusion as treatment strategies for stroke prevention in atrial fibrillation (AF) ... Targeting the left atrial appendage for AF-related stroke prevention: Why the heart team is necessary

Profiles


Cecilia Linde
Monday, 22 Jun 2015
Cecilia Linde speaks to Cardiac Rhythm News about her work on a research platform for new onset ... Cecilia Linde

Michael Gold
Wednesday, 03 Jun 2015
William Gold spoke to Cardiac Rhythm News about his involvement in various clinical trials, his ... Michael Gold

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions